The first issue of ACS Nano for 2017 features an article on the “Mechanisms and Barriers in Cancer Nanomedicine: Addressing Challenges, Looking for Solutions.” The article, co-...
Nanotechnology Characterization Lab
Eliminating suffering and death from cancer requires an unprecedented collaborative effort that leverages resources from government, industry, and academia. Working in concert with the National Institute of Standards and Technology (NIST) and the U.S. Food and Drug Administration (FDA), the National Cancer Institute (NCI) established the Nanotechnology Characterization Laboratory to perform preclinical efficacy and toxicity testing of nanoparticles.
The NCL serves as a national resource and knowledge base for all cancer researchers to facilitate the regulatory review of nanotechnologies intended for cancer therapies and diagnostics. By providing the critical infrastructure and characterization services to nanomaterial providers, the NCL accelerates the transition of basic nanoscale particles and devices into clinical applications, thereby reducing suffering and death from cancer.
There are multiple ways the NCL can help nanotech researchers and developers advance their technology, including characterization, reformulation, optimization, lead selection, method development, and more.
News & Updates
NCL’s Director, Scott McNeil, recently published a Correspondence article in Nature Reviews Materials.
NCL has created a focus group on LinkedIn, designed to connect researchers within the nanotech field.
Meet Us @
The National Congress of the Spanish Society of Immunology conference is hosted in Zaragoza, Spain, and takes place May 25-27.
The American Society of Clinical Oncology (ASCO) meeting will be held in Chicago, IL, June 2-6.